Addressing Knowledge Gaps in Ulcerative Colitis (UC) Care

This competitive program seeks to champion healthcare professional learning by providing education on new therapies and patient management considerations in ulcerative colitis (UC). This program seeks innovative, multi-channel educational approaches to support evidence-informed decisions in a rapidly evolving UC treatment landscape.

Project Types and Area of Interest

We are particularly interested in programs that focus on educational needs in UC, including but not limited to:

• Education of new oral therapies for UC including S1P modulators mechanism of action and data
• Education on transition from conventional to advance therapy in UC (treat to target and shared decision making)
• Burden of disease and management of isolated proctitis in UC

Eligibility

_You can learn more about this opportunity by visiting the funder's website._

• Only organizations are eligible to receive grants, not individuals or medical practice groups.
• The following may apply:
  • medical, nursing, allied health, and/or pharmacy professional schools
  • healthcare institutions (both large and small)
  • professional organizations/medical societies
  • medical education companies
  • other entities with a mission related to healthcare professional education and/or healthcare improvement
• If the project involves multiple departments within an institution and/or between different institutions organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
• The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
• The project/program lead must be an employee or independent contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.